ReviewFrontiers in microbiology2025
Oral microbiome contributions to metabolic syndrome pathogenesis.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Oral-Gut Microbiome Connection in Patients with Periodontitis: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Metabolic Syndrome and Periodontitis-From Shared Mechanisms to Interdisciplinary Care: A Narrative Review of Clinical Evidence.Journal of clinical medicine · 2026Review
- Article
- Oral Barrier Immunometabolism in Chronic Low-Grade Inflammation: Molecular Mechanisms and Systemic Implications.International journal of molecular sciences · 2026Review
- Association Between Continuous Consumption of Yogurt Fermented withJournal of clinical medicine · 2026Article
- Diet-Oral Microbiota Interactions and Salivary Biomarkers of Nutritional Health: A Narrative Review.Nutrients · 2026Review
- Intratumoral microbiome: the double-edged sword in remodeling cancer immunotherapy.Molecular cancer · 2026Review
- Objective tongue phenotyping identifies phenotypic heterogeneity in diabetic kidney disease: a dual-center clustering analysis.Frontiers in endocrinology · 2026Article
- Oral and Gut Health, (Neuro) Inflammation, and Central Sensitization in Chronic Pain: A Narrative Review of Mechanisms, Treatment Opportunities, and Research Agenda.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comprising over 700 bacterial species, the oral microbiome is the second most diverse microbial community in the human body after the gut microbiome. Currently, existing review literature suggests that gut microbiome events may play a significant role in the pathogenesis of metabolic syndrome, but the role of the oral microbiome in this disease has not yet been reviewed. The oral-gut microbiome axis refers to a bidirectional regulatory system that facilitates interaction between the oral cavity and the gut through microbial pathways. The microbiota from these two sites can migrate between each other via pathways such as swallowing and blood circulation, which may participate in disease development. In addition to the oral-gut axis, the oral microbiome itself may also influence disease pathogenesis. This review examines the potential contributions of the oral microbiome in the pathogenesis of metabolic syndrome, emphasizing its impact on insulin resistance, systemic inflammation and adipokine secretion. We explore therapeutic strategies targeting the oral microbiome which hold promise as future treatments for metabolic syndrome. Future research is needed to further elucidate the causal relationship between the oral microbiome and metabolic syndrome and to develop personalized microbiome-based therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.